<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Christopher Bourne, Devin</style></author><author><style face="normal" font="default" size="100%">Andrew Farraj, Samer</style></author><author><style face="normal" font="default" size="100%">Richard Rhees, Justin</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Current Practice of Mitigating Monoclonal Anti-CD38 Interference in Pretransfusion Compatibility Testing</style></title><secondary-title><style face="normal" font="default" size="100%">American Society for Clinical Laboratory Science</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">48-51</style></pages><doi><style  face="normal" font="default" size="100%">10.29074/ascls.2018000349</style></doi><volume><style face="normal" font="default" size="100%">31</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Anti-CD38 is a high-titer human IgG1 monoclonal antibody (mAb) that binds with high affinity and specificity to CD38, a 46-kDa type II transmembrane glycoprotein expressed on lymphoid, myeloid, and nonhematopoietic tissues.1⇓-3 The malignant cells in multiple myeloma (MM) often express high levels of CD38.4 Anti-CD38 mAb therapy has been shown to induce malignant cell death through antibody-dependent phagocytosis, complement-dependent cytotoxicity, and natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity.5 Daratumumab (DARA) (Darzalex, Janssen Pharmaceuticals) is the first anti-CD38 mAb approved by the Food and Drug Administration for the treatment of MM in patients who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or in patients who are double refractory to these agents.5⇓-7MM is a plasma cell malignancy characterized by the overproduction of mAbs, most commonly IgG or IgA. In serum protein electrophoresis (SPEP), the mAb is typically detected as M protein, a light chain derivative. M protein appears as a thin, dark band that produces a sharp peak in densitometric analysis. The high concentration of M protein may result in hyperviscosity of the blood and impaired kidney function. Uncontrolled proliferation of the malignant plasma cells frequently manifests as plasmacytomas in the bone marrow. The plasmacytomas secrete macrophage-activating cytokines that induce osteolytic activity resulting in bone lesions, hypercalcemia, and neuropathy. Lumbar pain is experienced as the first symptom by a substantial percentage of MM patients. As the disease progresses, patients experience transfusion-dependent anemia. Despite recent advances in treatment, MM remains incurable.A majority of patients receiving DARA therapy experience a significant reduction in M protein values,6 and DARA monotherapy has been shown to induce progression-free survival for a median of 6 months.6 However, monotherapy is less effective than combination therapy …</style></abstract></record></records></xml>